PL354144A1 - 2-pyrazolin-5-ones - Google Patents
2-pyrazolin-5-onesInfo
- Publication number
- PL354144A1 PL354144A1 PL00354144A PL35414400A PL354144A1 PL 354144 A1 PL354144 A1 PL 354144A1 PL 00354144 A PL00354144 A PL 00354144A PL 35414400 A PL35414400 A PL 35414400A PL 354144 A1 PL354144 A1 PL 354144A1
- Authority
- PL
- Poland
- Prior art keywords
- pyrazolin
- ones
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Emergency Medicine (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14656399P | 1999-07-30 | 1999-07-30 | |
PCT/US2000/020628 WO2001009121A2 (en) | 1999-07-30 | 2000-07-28 | 2-pyrazolin-5-ones_as tyrosine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
PL354144A1 true PL354144A1 (en) | 2003-12-29 |
Family
ID=22517965
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PL00354144A PL354144A1 (en) | 1999-07-30 | 2000-07-28 | 2-pyrazolin-5-ones |
Country Status (21)
Country | Link |
---|---|
EP (1) | EP1218373A2 (en) |
JP (1) | JP2003506368A (en) |
KR (1) | KR20020091829A (en) |
CN (1) | CN1193026C (en) |
AR (1) | AR032279A1 (en) |
AU (1) | AU6388900A (en) |
BG (1) | BG106392A (en) |
BR (1) | BR0012896A (en) |
CA (1) | CA2380644A1 (en) |
CZ (1) | CZ2002302A3 (en) |
HK (1) | HK1049154A1 (en) |
HU (1) | HUP0400540A3 (en) |
IL (1) | IL147757A0 (en) |
MX (1) | MXPA02001088A (en) |
NO (1) | NO20020487L (en) |
NZ (1) | NZ516850A (en) |
PL (1) | PL354144A1 (en) |
SK (1) | SK1512002A3 (en) |
TR (1) | TR200200928T2 (en) |
WO (1) | WO2001009121A2 (en) |
ZA (1) | ZA200200477B (en) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6455525B1 (en) | 1999-11-04 | 2002-09-24 | Cephalon, Inc. | Heterocyclic substituted pyrazolones |
US6916798B2 (en) * | 2001-08-03 | 2005-07-12 | Vertex Pharmaceuticals Incorporated | Inhibitors of GSK-3 and uses thereof |
WO2005002574A1 (en) * | 2003-06-24 | 2005-01-13 | Actelion Pharmaceuticals Ltd | Pyrazolidinedione derivatives and their use as platelet aggregation inhibitors |
WO2005012255A1 (en) * | 2003-08-01 | 2005-02-10 | Mitsubishi Pharma Corporation | Remedy for inflammatory joint diseases |
JP4716873B2 (en) * | 2003-10-14 | 2011-07-06 | 聰 竹尾 | Agent for improving intellectual disability |
GB0329617D0 (en) * | 2003-12-23 | 2004-01-28 | Astex Technology Ltd | Pharmaceutical compounds |
US7498342B2 (en) | 2004-06-17 | 2009-03-03 | Plexxikon, Inc. | Compounds modulating c-kit activity |
WO2006124874A2 (en) * | 2005-05-12 | 2006-11-23 | Kalypsys, Inc. | Inhibitors of b-raf kinase |
JPWO2006129587A1 (en) * | 2005-05-30 | 2009-01-08 | 株式会社ジーンケア研究所 | Pharmaceutical composition containing pyrazolone derivative |
EP1905762A1 (en) * | 2005-05-30 | 2008-04-02 | Genecare Research Institute Co., Ltd | Pyrazolone derivative |
US7371862B2 (en) * | 2005-11-11 | 2008-05-13 | Pfizer Italia S.R.L. | Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
DE102005057924A1 (en) * | 2005-12-05 | 2007-06-06 | Merck Patent Gmbh | pyridazinone derivatives |
MY150667A (en) | 2005-12-09 | 2014-02-28 | Gilead Pharmasset Llc | Antiviral nucleosides |
ES2429290T3 (en) | 2006-10-10 | 2013-11-14 | Gilead Pharmasset Llc | Preparation of ribofuranosylpyrimidine nucleosides |
WO2008063888A2 (en) | 2006-11-22 | 2008-05-29 | Plexxikon, Inc. | Compounds modulating c-fms and/or c-kit activity and uses therefor |
US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
JP2010533729A (en) | 2007-07-17 | 2010-10-28 | プレキシコン,インコーポレーテッド | Compounds and methods for kinase regulation, and adaptations therefor |
KR100987557B1 (en) * | 2008-03-18 | 2010-10-12 | 이화여자대학교 산학협력단 | Composition for the prevention or treatment of restenosis |
EP2367798B1 (en) * | 2008-11-20 | 2018-02-28 | Northwestern University | Pyrazolone derivatives useful in the treatment of amyotrophic lateral sclerosis |
US9145424B2 (en) | 2008-11-20 | 2015-09-29 | Northwestern University | Treatment of amyotrophic lateral sclerosis |
KR20110104074A (en) | 2008-12-23 | 2011-09-21 | 파마셋 인코포레이티드 | Synthesis of purine nucleosides |
MX2011008303A (en) | 2009-04-03 | 2011-11-29 | Plexxikon Inc | Propane- i-sulfonic acid {3- [5- (4 -chloro-phenyl) -1h-pyrrolo [2, 3-b] pyridine-3-carbonyl] -2, 4-difluoro-pheny l } -amide compositions and uses thereof. |
US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
TWI598358B (en) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | Nucleoside phosphoramidates |
PE20121327A1 (en) | 2009-11-06 | 2012-10-18 | Plexxikon Inc | COMPOUNDS AND METHODS FOR THE MODULATION OF KINASES, AND INDICATIONS THEREOF |
PT2752422T (en) | 2010-03-31 | 2017-11-07 | Gilead Pharmasset Llc | Stereoselective synthesis of phosphorus containing actives |
PT3042910T (en) | 2010-11-30 | 2019-04-16 | Gilead Pharmasset Llc | 2'-spiro-nucleosides for use in the therapy of hepatitis c |
RS58455B1 (en) | 2011-02-07 | 2019-04-30 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
AR085279A1 (en) | 2011-02-21 | 2013-09-18 | Plexxikon Inc | SOLID FORMS OF {3- [5- (4-CHLORINE-PHENYL) -1H-PIRROLO [2,3-B] PIRIDINA-3-CARBONIL] -2,4-DIFLUOR-PHENIL} -AMIDE OF PROPANE ACID-1- SULFONIC |
US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
US9150570B2 (en) | 2012-05-31 | 2015-10-06 | Plexxikon Inc. | Synthesis of heterocyclic compounds |
KR101684955B1 (en) * | 2012-07-23 | 2016-12-12 | 주식회사유한양행 | Furan-containing fused cyclic compound or its salt and pharmaceutical composition comprising the same |
CN106029640B (en) | 2014-02-14 | 2018-08-24 | 泰普斯特医疗公司 | Pyrazolinone compounds and application thereof |
CN105037269B (en) * | 2015-07-10 | 2018-01-19 | 中国人民解放军第二军医大学 | Substituted pyrazolecarboxylic ketone secretory protease inhibitors and preparation method thereof |
HUE057178T2 (en) | 2017-08-15 | 2022-04-28 | Agios Pharmaceuticals Inc | Pyruvate kinase activators for use in treating blood disorders |
KR102625224B1 (en) * | 2018-10-31 | 2024-01-15 | 주식회사 큐로젠 | Composition for preventing, improving or treating autoimmune diseases comprising pyrazol-one derivatives |
CN111793032B (en) * | 2019-04-08 | 2021-11-19 | 四川省中医药科学院 | Pyrazolone compounds and preparation method and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4369310A (en) * | 1979-11-19 | 1983-01-18 | Ciba-Geigy Ltd. | Bleachable dyes |
JPH078851B2 (en) * | 1985-07-29 | 1995-02-01 | 鐘淵化学工業株式会社 | 3-phenylthiomethylstyrene derivative |
JPS6229570A (en) * | 1985-07-29 | 1987-02-07 | Kanegafuchi Chem Ind Co Ltd | 3,5-diisopropylbenzylidene heterocyclic compound |
JP2678822B2 (en) * | 1990-06-04 | 1997-11-19 | 富士写真フイルム株式会社 | Silver halide photographic material |
-
2000
- 2000-07-28 AU AU63889/00A patent/AU6388900A/en not_active Abandoned
- 2000-07-28 SK SK151-2002A patent/SK1512002A3/en unknown
- 2000-07-28 BR BR0012896-1A patent/BR0012896A/en not_active IP Right Cessation
- 2000-07-28 IL IL14775700A patent/IL147757A0/en unknown
- 2000-07-28 EP EP00950852A patent/EP1218373A2/en not_active Withdrawn
- 2000-07-28 TR TR2002/00928T patent/TR200200928T2/en unknown
- 2000-07-28 NZ NZ516850A patent/NZ516850A/en unknown
- 2000-07-28 MX MXPA02001088A patent/MXPA02001088A/en unknown
- 2000-07-28 PL PL00354144A patent/PL354144A1/en not_active Application Discontinuation
- 2000-07-28 WO PCT/US2000/020628 patent/WO2001009121A2/en not_active Application Discontinuation
- 2000-07-28 HU HU0400540A patent/HUP0400540A3/en unknown
- 2000-07-28 CN CNB008136823A patent/CN1193026C/en not_active Expired - Fee Related
- 2000-07-28 CA CA002380644A patent/CA2380644A1/en not_active Abandoned
- 2000-07-28 JP JP2001514324A patent/JP2003506368A/en not_active Withdrawn
- 2000-07-28 KR KR1020027001343A patent/KR20020091829A/en not_active Application Discontinuation
- 2000-07-28 CZ CZ2002302A patent/CZ2002302A3/en unknown
- 2000-07-31 AR ARP000103955A patent/AR032279A1/en unknown
-
2002
- 2002-01-18 ZA ZA200200477A patent/ZA200200477B/en unknown
- 2002-01-30 NO NO20020487A patent/NO20020487L/en not_active Application Discontinuation
- 2002-02-06 BG BG106392A patent/BG106392A/en unknown
- 2002-12-23 HK HK02109301.3A patent/HK1049154A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR032279A1 (en) | 2003-11-05 |
IL147757A0 (en) | 2002-08-14 |
HUP0400540A3 (en) | 2004-09-28 |
KR20020091829A (en) | 2002-12-06 |
WO2001009121A2 (en) | 2001-02-08 |
TR200200928T2 (en) | 2002-09-23 |
ZA200200477B (en) | 2003-06-25 |
AU6388900A (en) | 2001-02-19 |
MXPA02001088A (en) | 2003-09-22 |
NZ516850A (en) | 2004-09-24 |
CA2380644A1 (en) | 2001-02-08 |
NO20020487D0 (en) | 2002-01-30 |
BG106392A (en) | 2002-12-29 |
EP1218373A2 (en) | 2002-07-03 |
SK1512002A3 (en) | 2002-11-06 |
HUP0400540A2 (en) | 2004-06-28 |
CN1377346A (en) | 2002-10-30 |
CZ2002302A3 (en) | 2002-06-12 |
CN1193026C (en) | 2005-03-16 |
HK1049154A1 (en) | 2003-05-02 |
NO20020487L (en) | 2002-03-12 |
BR0012896A (en) | 2002-06-18 |
JP2003506368A (en) | 2003-02-18 |
WO2001009121A3 (en) | 2002-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60018571D1 (en) | Hernienprothese | |
DE60033307D1 (en) | Heteroalkylamino-substituierte bicyclische stickstoffheterocyclen | |
DE60008112D1 (en) | Respiratorisches syncytialvirus replikation inhibitoren | |
DE60008382D1 (en) | Respiratorisches syncytialvirus replikation inhibitoren | |
DE60037335D1 (en) | Polymerizationsverfahren | |
DE50002490D1 (en) | Polyester-polyetherblockcopolymere | |
DE50008011D1 (en) | Thixotropierungsmittel | |
IL147757A0 (en) | 2-pyrazolin-5-ones | |
DE60018288D1 (en) | Polyphenylensulfidlegierungszusammensetzung | |
DE60027722D1 (en) | Aspartyl-protease inhibitoren | |
DE50002614D1 (en) | Sigma-delta-modulator | |
DE60034237D1 (en) | Ferrofluidabdichtung | |
DE60007505D1 (en) | Propargyletherderivate | |
DE60028360D1 (en) | Ptk-chipthermistor | |
DE60036727D1 (en) | Differentialverstärker | |
DE60011809D1 (en) | Oxcarbazepinsuspension | |
DE50000137D1 (en) | Spirofluorenopyrane | |
DE59909975D1 (en) | Testleck | |
DE10081629D2 (en) | Seilzugbefestigung | |
DE60001313D1 (en) | Imidazodiazepinderivate | |
DE50009469D1 (en) | Common-rail-injektor | |
DE60012950D1 (en) | Polyacetalharzzusammensetzung | |
DE60044740D1 (en) | Hochtemperatur-differentialrefraktometer | |
DE50012999D1 (en) | Stirnwandisolation | |
DE60037536D1 (en) | Polypeptidhormon phosphatonin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
REFS | Decisions on refusal to grant patents (taken after the publication of the particulars of the applications) |